{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"288.83","value":"556080.86"},{"groupId":"OG001","spread":"276.50","value":"610142.64"},{"groupId":"OG002","spread":"159.86","value":"1307054.13"},{"groupId":"OG003","spread":"188.93","value":"1390556.32"},{"groupId":"OG004","spread":"80.39","value":"1956613.78"},{"groupId":"OG005","spread":"104.12","value":"2052280.38"},{"groupId":"OG006","spread":"226.53","value":"1427277.29"},{"groupId":"OG007","spread":"145.22","value":"1287032.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"23"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"AUC (0-28) of JCARH125 CAR T cells in the blood as determined by quantitative polymerase chain reaction (qPCR) to detect the JCARH125 transgene.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"JCARH125 IV at dose level 50 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG000","title":"Phase 1 50 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 150 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG001","title":"Phase 1 150 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 300 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG002","title":"Phase 1 300 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 450 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG003","title":"Phase 1 450 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG004","title":"Phase 1 600 x 10^6 Cells"},{"description":"2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG005","title":"Phase 1 Anakinra 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG006","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG007","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who have the necessary PK measurements to provide interpretable results for this specific parameter of interest","reportingStatus":"POSTED","timeFrame":"From JCARH125 infusion through 28 days after the infusion","title":"Area Under the Concertation-Time Curve (AUC) From Time Day 1 to Day 29 [AUC (0-28 Days)]","type":"SECONDARY","unitOfMeasure":"Day*copies/UG"}